Hoffmann-la Roche Inc.

F. Hoffmann-la Roche Ag

Helsinn Healthcare Sa

Andreas Koblet

Henner Knust

Giuseppe Cecere

Maria-Clemencia Hernandez

Matthias Heinrich Nettekoven

Hasane Ratni

Andrew William Thomas

Bernd Buettelmann

Claus Riemer

Torsten Hoffmann

Valerie Runtz-Schmitt

Emmanuel Pinard

Patrick Schnider

Jens-Uwe Peters

Luca Claudio Gobbi

Heinz Stadler

Katrin Groebke Zbinden

Bo Han

Walter Vifian

Andrew Sleight

Angélique Patiny-Adam

Andres Miguel Olivares Morales

Guido Galley

Caterina Bissantz

Anja Limberg

Bjoern Bartels

Michael Reutlinger

Bernhard Fasching

Sandra Steiner

Philippe Jablonski

Nicolas Zorn

Andrés Miguel Olivares Morales

Eoin Cornelius O'Connor

Jaclyn Ivy Wamsteeker Cusulin

Christoph Funk

Frédéric Knoflach

Guillaume DÉCORET

Eoin Cornelius O`CONNOR

Jaclyn Wamsteeker Cusulin

The invention provides novel heterocyclic compounds having the general formula (I), and pharmaceutically acceptable salts thereof, wherein the variables are as described herein. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds for the treatment or prevention of acute neurological disorders, chronic neurological disorders and/or cognitive disorders.

Benzodiazepine derivatives as GABA A gamma 1 PAM

The invention provides novel compounds having the general formula (I) or (II) wherein R, R, R, R, W, Y and Z are as described herein, compositions including the compounds and methods of using the compounds.

Isoxazolyl ether derivatives as GABA&#x3b1;5 PAM

Compounds having the general formula (I) wherein R, R, R, R, Rand X are as described herein, compositions including the compounds and methods of using the compounds.

Substituted benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepines as GABA A GAMMA1 positive allosteric modulators

Compounds having the formula (I) wherein R, R, R, R, R, R, X, Y and Z are as described herein, compositions including the compounds and methods of using the compounds.

The present application relates to compounds of formula wherein R, R, R, R, and n are defined hereinor to a pharmaceutically active salt thereof. The present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).

Pyrrolidine compounds

The present invention relates to compounds of formula wherein R, R, R, R, Z, and n are as defined hereinor to a pharmaceutically active salt thereof. Compounds of the invention are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).

Pyrrolidine derivatives

The present invention provides a method for the treatment of schizophrenia which comprises administering a compound of formula 

Dual NK1/NK3 receptor antagonists

The present invention relates to compounds of formula I wherein R, R, R, Ar and n are as defined herein and pharmaceutically active salts, racemic mixtures, enantiomers, optical isomers or tautomeric forms thereof. The compounds can be used for the treatment of depression, anxiety or schizophrenia.

Pyrrolidine derivatives as NK2 receptor antagonists

The present invention is concerned with isoxazol-4-yl-oxadiazole derivatives of formula wherein This class of compounds has high affinity and selectivity for GABA A &#x3b1;5 receptor binding sites and might be useful as cognitive enhancer or for the treatment of cognitive disorders like Alzheimer's disease.

Aryl-isoxazolo-4-yl-oxadiazole derivatives

The present invention relates to compounds of formula I wherein

NK-1 receptor antagonists

Growing community of inventors

Bottmingen, Switzerland

Andreas Koblet